Pharmacological and Non-pharmacological Treatments of Sleep Disorders in Parkinson's Disease

Taximaimaiti, Reyisha; Luο, Xingguang; Wang, Xiaoping

doi:10.2174/1570159x19666210517115706

Cited by 21 publications

(14 citation statements)

References 184 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another alternative that has been shown to improve the regulation of the sleep–wake transition, thus improving sleep quality, is physical exercise. In addition, a significant benefit has been observed in physical activities in which a cognitive element is introduced, such as Tai Chi [ 94 ]. Cognitive behavioural therapy is one of the alternatives that has shown favourable results in the treatment of sleep disorders in PD.…”

Section: Resultsmentioning

confidence: 99%

Current Treatments and New, Tentative Therapies for Parkinson’s Disease

Pardo-Moreno¹,

García‐Morales

Suleiman‐Martos

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a neurodegenerative pathology, the origin of which is associated with the death of neuronal cells involved in the production of dopamine. The prevalence of PD has increased exponentially. The aim of this review was to describe the novel treatments for PD that are currently under investigation and study and the possible therapeutic targets. The pathophysiology of this disease is based on the formation of alpha-synuclein folds that generate Lewy bodies, which are cytotoxic and reduce dopamine levels. Most pharmacological treatments for PD target alpha-synuclein to reduce the symptoms. These include treatments aimed at reducing the accumulation of alpha-synuclein (epigallocatechin), reducing its clearance via immunotherapy, inhibiting LRRK2, and upregulating cerebrosidase (ambroxol). Parkinson’s disease continues to be a pathology of unknown origin that generates a significant social cost for the patients who suffer from it. Although there is still no definitive cure for this disease at present, there are numerous treatments available aimed at reducing the symptomatology of PD in addition to other therapeutic alternatives that are still under investigation. However, the therapeutic approach to this pathology should include a combination of pharmacological and non-pharmacological strategies to maximise outcomes and improve symptomatological control in these patients. It is therefore necessary to delve deeper into the pathophysiology of the disease in order to improve these treatments and therefore the quality of life of the patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Current Treatments and New, Tentative Therapies for Parkinson’s Disease

Pardo-Moreno¹,

García‐Morales

Suleiman‐Martos

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…However, the effect of melatonin on EDS remains unclear. Of note, melatonin is recommended as the first-line therapy because it reduces RBD-related injuries with fewer side effects than clonazepam [211]. In the context of AD, one recent systematic review showed that melatonin shortens the sleep onset latency and increases sleep duration [212].…”

Section: Melatonin and Melatonin Receptor Agonistsmentioning

confidence: 99%

Circadian disruption and sleep disorders in neurodegeneration

Shen

Xie

et al. 2023

Transl Neurodegener

View full text Add to dashboard Cite

Disruptions of circadian rhythms and sleep cycles are common among neurodegenerative diseases and can occur at multiple levels. Accumulating evidence reveals a bidirectional relationship between disruptions of circadian rhythms and sleep cycles and neurodegenerative diseases. Circadian disruption and sleep disorders aggravate neurodegeneration and neurodegenerative diseases can in turn disrupt circadian rhythms and sleep. Importantly, circadian disruption and various sleep disorders can increase the risk of neurodegenerative diseases. Thus, harnessing the circadian biology findings from preclinical and translational research in neurodegenerative diseases is of importance for reducing risk of neurodegeneration and improving symptoms and quality of life of individuals with neurodegenerative disorders via approaches that normalize circadian in the context of precision medicine. In this review, we discuss the implications of circadian disruption and sleep disorders in neurodegenerative diseases by summarizing evidence from both human and animal studies, focusing on the bidirectional links of sleep and circadian rhythms with prevalent forms of neurodegeneration. These findings provide valuable insights into the pathogenesis of neurodegenerative diseases and suggest a promising role of circadian-based interventions.

show abstract

“…Patients with insomnia often suffer from anxiety, depression and other psychological emotions, which aggravate the degree of illness. For these patients, nisamide, agomelatine, and levodopa-carbidopa enteral gel can be selected for treatment [11].…”

Section: Treatmentmentioning

confidence: 99%

Sleep disorders in Parkinson's patients

Hu¹

2023

HSET

View full text Add to dashboard Cite

Sleep disorder is one of the most common non-motor symptoms of Parkinson's disease and can occur at any stage of the disease. Clinical symptoms are decreased total sleep time, decreased sleep efficiency (difficulty falling asleep, easy awakening, etc.), rapid eye movement, excessive daytime sleepiness, often accompanied by cognitive impairment, thinking and emotional disorders, etc. It is a huge burden, so it is crucial to pay attention to sleep disorder in Parkinson's patients. This article introduces the pathogenic mechanism and treatment methods of insomnia, restless legs syndrome, sleep apnoea and excessive daytime sleepiness.

show abstract

Pharmacological and Non-pharmacological Treatments of Sleep Disorders in Parkinson's Disease

Cited by 21 publications

References 184 publications

Current Treatments and New, Tentative Therapies for Parkinson’s Disease

Current Treatments and New, Tentative Therapies for Parkinson’s Disease

Circadian disruption and sleep disorders in neurodegeneration

Sleep disorders in Parkinson's patients

Contact Info

Product

Resources

About